HLA-G and digestive system disorder: Combination therapy reported more leukopenia (16% vs. 13%); respiratory, thoracic, and mediastinal disorders (20% vs. 18%); increased β2-microglobulin (11% vs. 3%); and decreased blood iron (16% vs. 13%), but smaller increases in transaminase (20% vs. 26%) and gastrointestinal disorders (13% vs. 16%).